Skip to main content

      TrendLens

      Managing drug spend is a big part of keeping overall health care costs in check, and we’re here to help. TrendLens gives you a clear, quarterly view of the trends and drivers shaping pharmacy spend. It turns data into practical insights you can use to improve affordability, access and outcomes.

      Q1 | 2026 Trend highlights

       

      • Illustration of a scale

        GLP-1 pressure continued to ease, helping lower non-specialty trend. 

      • Icon

        Specialty remained the primary driver of pharmacy costs, with HIV emerging as a leading trend driver. 

      • Icon

        Regulatory and market forces are playing a growing role in shaping pharmacy trend. 

      See what shaped Q1 2026 trend and what it could mean for your plan strategy.

      Download the report
      Illustration of a document with the CVS Health heart logo on it

       

      Missed the last update? View key insights from our Q4 2025 Trend highlights.

      A photograph of Ed DeVaney, EVP & President of CVS Caremark, to accompany his quote.

      We’re the only ones in the supply chain whose sole purpose is to reduce the cost of prescriptions. We’re best at it and confident that we’ll continue to deliver the right drug at the right price to deliver the right clinical outcome.

      Ed DeVaney

      EVP & President, CVS Caremark

      A photograph of Ed DeVaney, EVP & President of CVS Caremark, to accompany his quote.

      Delivering exceptional member and client experiences

      Lowering costs is a team effort. With simplified pricing, flexible plan designs and smart, member‑focused utilization management, we help you take control of spend. And for members, we make benefits easy to understand and use, helping lower out‑of‑pocket costs, supporting better health outcomes and improving their overall experience. The impact speaks for itself.

       

      $4.46B

      in expected savings from 2026 formularies*

      Three children greet their father who has just arrived home from work. They’re happy and excited to see him. There’s a CVS Pharmacy box with prescriptions on the kitchen island.

      88%

      of members paid $0 for biosimilars*

      $8.38

      average out‑of‑pocket for a 30‑day supply*

      79%

      clients agree CVS Caremark supports their cost control goals*

      Learn more

      See how we keep drug prices down while improving member health.

      Visit business.caremark.com
      A photograph of a business meeting in a professional setting, with a close up of an older woman leading the conversation.

      Help me stay ahead

      Contact us

      • *FOR $4.46B IN EXPECTED SAVINGS FROM 2026 FORMULARIES CLAIM: CVS Health Trade Finance, 2025. Client savings are determined using cumulative value over a 3-year period (upcoming year, current year and prior year).

      • *FOR 88% OF MEMBERS PAID $0 FOR BIOSIMILARS CLAIM: CVS Health Analytics, 2026. CVS Commercial clients.

      • *FOR $8.38 AVERAGE OUT-OF-POCKET FOR A 30-DAY SUPPLY CLAIM: CVS Health Analytics, 2026. Cost savings reflect first quarter 2026.

      • *FOR 79% CLIENT SUPPORT CLAIM: CVS Caremark member experience survey, 2025. Caremark Client Relationship Management Survey, Spring 2026

       

      All data sharing complies with applicable law, our information firewall and any applicable contractual limitations. Actual results may vary depending on benefit plan design, member demographics, programs implemented by the plan and other factors.